Literature DB >> 9350605

Decreased first trimester uric acid production in future preeclamptic patients.

C L de Jong1, K M Paarlberg, H P van Geijn, E J Schipper, A Bast, P J Kostense, G A Dekker.   

Abstract

The relationship between first trimester uric acid production and later development of pregnancy induced hypertensive disorders (PIHD) was investigated. An anti-oxidant role for uric acid has been mentioned. Since uric acid and fibronectin (PF) are both markers of preeclampsia, the relationship between these two substances was also studied. Controls (n = 72) and patients with PIHD (n = 120) were selected. Uric acid was measured in serum and 24-hours urine samples (uric acid excretion) and PF in blood plasma in 270 nulliparous women at 13 +/- 2 weeks of gestation. Uric acid excretion was significantly lower in the first trimester in a group of patients who later develop PIHD as compared to patients who remain normotensive (p < 0.05), especially when corrected for body weight (p < 0.01). Patients with elevated PF levels in the first trimester showed a significantly lower uric acid excretion than patients with normal PF levels (p < 0.05). The data show diminished uric acid production in patients who will likely develop preeclampsia suggesting an impaired anti-oxidant production in the first trimester. This observation fits well with the hypothesis that an imbalance between anti-oxidant and oxidants plays an important role in the pathogenesis of preeclampsia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350605     DOI: 10.1515/jpme.1997.25.4.347

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  2 in total

1.  First trimester uric acid and adverse pregnancy outcomes.

Authors:  S Katherine Laughon; Janet Catov; Robert W Powers; James M Roberts; Robin E Gandley
Journal:  Am J Hypertens       Date:  2011-01-20       Impact factor: 2.689

2.  Uric acid: a clinically useful marker to distinguish preeclampsia from gestational hypertension.

Authors:  Richard J Johnson; Mehmet Kanbay; Duk-Hee Kang; Laura Gabriela Sánchez-Lozada; Daniel Feig
Journal:  Hypertension       Date:  2011-08-29       Impact factor: 10.190

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.